Immunotherapy before surgery for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether giving immunotherapy before surgery can help people with advanced kidney cancer. The goal is to see if waiting on surgery and starting with medication that boosts the immune system is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 79 years old.
- You need a diagnosis of clear cell kidney cancer (the most common type).
- Your cancer has spread to lymph nodes or other organs, but not too many spots (5 or fewer in up to 3 organs).
- You must be in good general health (able to care for yourself, no major heart, liver, or kidney problems).
- You cannot have had other cancers in the last 5 years (except for treated skin cancer or cervical pre-cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs — an immunotherapy (toripalimab) and a targeted therapy (axitinib) — as the first treatment for advanced kidney cancer. The approach may shrink the tumor before deciding whether and when to remove the kidney surgically.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This study tests whether taking axitinib plus an immunotherapy drug (PD-1) before surgery can help people with kidney cancer live longer without the cancer coming back. It’s focused on people who have a higher-risk kidney tumor based on scans and pathology findings.
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
This study compares two treatment plans for advanced kidney cancer: having surgery to remove the kidney tumor right away along with immunotherapy drugs (ipilimumab and nivolumab), versus starting the immunotherapy first and doing surgery later. The goal is to see if delaying surgery is just as good or better.
This trial tests a new drug (JS004) combined with an existing immunotherapy (toripalimab) for kidney cancer that has progressed after previous immunotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Clear-cell Metastatic Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.